Comparative Pharmacology
Head-to-head clinical analysis: FLUOR OP versus PRED FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOR OP versus PRED FORTE.
FLUOR-OP vs PRED FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammatory responses.
Corticosteroid that binds to glucocorticoid receptors, causing inhibition of phospholipase A2, arachidonic acid release, and synthesis of inflammatory mediators. Reduces inflammation by suppressing leukocyte infiltration and cytokine production.
2 drops of 0.1% solution into the affected eye(s) every 15 minutes for 4 doses, then every 30 minutes for 2 doses, then every 1-2 hours for 24-48 hours, then tapering over 1-2 weeks; alternatively, 0.5 cm ribbon of 0.05% ointment into the conjunctival sac 4-6 times daily.
1-2 drops in the conjunctival sac every 1-2 hours during the day and every 4 hours at night initially, then taper to every 4-8 hours as inflammation resolves. Severe cases may require hourly dosing.
None Documented
None Documented
Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
2-3 hours (terminal) after IV administration; for topical ophthalmic use, systemic half-life is similar but local ocular half-life is prolonged due to corneal reservoir.
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%).
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 80% of elimination, with biliary/fecal elimination <20%.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid